Abstract 1880P
Background
Physicians must help patients to maintain motivation and resolve barriers to adherence to treatment, but this does not happen in many cases. The impact of cancer in the coming years will have devastating consequences for the health system since it is the third cause of mortality in the country. Therefore, a substantial change in medical education, health policies is imperative. They are future specialists, the attitudinal barriers could limit their skills and abilities in the task for general surgeons, gynecologists, otolaryngologists, and anesthetists. To detect and change barriers, implement a strategy of 180 minutes in a reflexive focus group.
Methods
Descriptive, non-blind study approved by the Research Ethics Committee (ON23-00003), informed consent was requested from 51 medical residents of the surgical areas of a general hospital who attended a psychoeducational focus group in 2 frequencies, they answered the survey about their beliefs and attitudes regarding the care of cancer patients. 3 key questions were analyzed to ensure knowledge together with reflection, reinforcing empathic attitudes and team collaboration of the participants.
Results
The subjects correctly considered the definition of oncology pre and post-intervention (84 vs 91%), that the treating physician had to give the diagnosis (55 vs 92%) that there is no correct answer for how long a patient would live (89 vs 96%), The term used by the patient to name the cancer doesn´t matter as long as they understand the disease (32 vs 42%), That they should not join the conspiracy of silence proposed by the patient or family (77 vs 91%) If they believed that there is treatment in any stage of cancer (55 vs 87%), if they should care for patients with cancer with a CPR indication vs other chronic patients with hypertensive crisis and DM (64 vs 81%), if they considered palliative care and psycho-oncology for diagnostic phases (63 vs 85%). In the qualitative aspect they left satisfied and mostly looking forward to new sessions that would allow them to carry out their work and education.
Conclusions
There was a percentage impact in generating substantive changes in the opinion of the subjects; this first step should be followed up with more studies and is of relevance to medical educators.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universidad Autónoma de Nuevo León.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05